Australia's BlinkLab jumps on US ethics approval for diagnostic trial

BlinkLab

30/06/2025 02:05

** BlinkLab BB1.AX jumps as much as 10.4% to a record high of A$0.585

** Digital healthcare firm receives U.S. ethics approval for the main study phase of its diagnostic trial

** Says trial will evaluate BlinkLab Dx 1 technology, designed to detect and diagnose autism

** BB1 last up 7.6%, taking YTD gains to 89%

 (Reporting by Rajasik Mukherjee in Bengaluru)

 ((Rajasik.Mukherjee@thomsonreuters.com))